GlassScriptPhysician profile
Brian K Dublin
NPI 1386638922
$1,271.57
in general payments reported to CMS, 2019-2025
24 companies · $45.16 in 2025
The $45.16 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $36.33 · 2021: $204 · 2022: $326 · 2023: $338 · 2024: $178 · 2025: $45.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $199.16 | 2020-2023 | Mitraclip |
| Merck Sharp & Dohme LLC | $129.91 | 2022-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $128.97 | 2022 | |
| Janssen Pharmaceuticals, INC | $117.19 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $88.59 | 2019-2022 | |
| Amgen INC. | $85.82 | 2021-2024 | Repatha |
| Boston Scientific Corporation | $67.98 | 2023-2024 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon |
| Sanofi-Aventis U.S. LLC | $56.84 | 2019-2020 | |
| Pfizer INC. | $55.98 | 2021-2023 | |
| Cvrx, INC. | $45.16 | 2025 | Barostim Neo System |
| Esperion Therapeutics, INC. | $37.65 | 2021-2022 | |
| Heartflow, INC. | $33.37 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $30.83 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $29.49 | 2021-2024 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $23.62 | 2023 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $21.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.53 | 2021 | |
| Amarin Pharma, INC. | $16.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2021 | |
| Novo Nordisk INC | $14.44 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.08 | 2021 | |
| Ge Healthcare | $13.60 | 2019 | |
| Irhythm Technologies, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dublin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.